PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Mosaiques Diagnostics GmbH, Hannover, Germany.\', \'Division of Nephrology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.\', \'Division of Endocrinology and Metabolism, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.\', \'Department of Nephrology and Kuratorium for Dialysis and Transplantation (KfH) Renal Unit, Hospital St. Georg, Leipzig, Germany.\', \'Department of Internal Medicine 2 (Nephrology, Rheumatology, Endocrinology), Martin-Luther-University Halle/Wittenberg, Halle, Germany.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1002/pmic.202100160
?:hasPublicationType
?:journal
  • Proteomics
is ?:pmid of
?:pmid
?:pmid
  • 34477316
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.435
?:rankingScore_hIndex
  • 149
?:title
  • SGLT2-Inhibition reverts urinary peptide changes associated with severe COVID-19: An in-silico proof-of-principle of proteomics-based drug repurposing.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34477316>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34477316>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all